The World Health Organization (WHO) officially recommended two new treatments against Covid-19 on Friday in very specific cases, for a total now increased to five.
To discover
New health pass rules from January 15: all the answers to your questions
LiveCovid-19: the obligation to wear a mask outdoors in Paris suspended by the courts
In an opinion published in the medical journal
The BMJ
, WHO experts recommend treatment with synthetic antibodies, sotrovimab, and a drug commonly used against rheumatoid arthritis, baricitinib.
Both are not intended for just any patient.
Read alsoOmicron: the hope of finally emerging from the pandemic
Sotrovimab is recommended for patients who have contracted mild Covid but are at high risk of hospitalization. Its benefit for patients who are not at risk is considered too low. Baricitinib is recommended for “
patients with severe or critical Covid
”, to whom it must be administered “
in combination with corticosteroids
”. In these patients, it "
improves survival rates and reduces the need for mechanical ventilation
."
Until then, the WHO recommended three treatments: synthetic antibodies sold under the name Ronapreve, since September 2021, a class of drugs called "interleukin 6 antagonists" (tocilizumab and sarilumab), since July 2021 , and systematic corticosteroids for severely affected patients, since September 2020.
Sotrovimab concerns the same type of patients as Ronapreve. "
Their effectiveness against new variants such as Omicron is still uncertain
", however qualify the WHO experts. Similarly, baricitinib “
has the same effects
” as interleukin-6 antagonists, and should be administered to the same patients. “
When both are available
”, it is therefore necessary to choose which of the two to use “
according to the cost, the availability and the experience of the caregivers
”, recommend the WHO experts.
Baricitinib belongs to a family of drugs called “Janus kinase inhibitors” and is used against rheumatoid arthritis, an autoimmune disease.
However, the other drugs in this family (ruxolitinib and tofacitinib) should not be used against Covid, say WHO experts.
There is a lack of data on their efficacy or side effects in this indication.
WHO anti-Covid treatment recommendations are regularly updated, based on clinical trials conducted on different types of patients.
However, the therapeutic arsenal remains limited.
In recent months, the WHO has rejected the use of several treatments: plasma injection of recovered Covid patients, ivermectin and hydroxychloroquine.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/PCE7NMB26ZDVRIQX2R26JSNH6A.jpg)
